Document is current
Any future updates will be listed below
-
Authors
Alečković, Maša http://orcid.org/0000-0001-5653-8502
Cristea, Simona
Gil Del Alcazar, Carlos R.
Yan, Pengze
Ding, Lina
Krop, Ethan D.
Harper, Nicholas W.
Rojas Jimenez, Ernesto
Lu, Donghao
Gulvady, Anushree C.
Foidart, Pierre
Seehawer, Marco
Diciaccio, Benedetto
Murphy, Katherine C. http://orcid.org/0000-0002-5962-9896
Pyrdol, Jason
Anand, Jayati
Garza, Kodie
Wucherpfennig, Kai W. http://orcid.org/0000-0002-1829-302X
Tamimi, Rulla M.
Michor, Franziska http://orcid.org/0000-0003-4869-8842
Polyak, Kornelia http://orcid.org/0000-0002-5964-0382
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35 CA197623, CA193461, CA080111)
- License Information
-
More Information
Article History
Received: 8 February 2022
Accepted: 16 November 2022
First Online: 7 December 2022
Competing interests
: The authors declare competing financial interests: K.P. serves on the Scientific Advisory Board of Acrivon Therapeutics, Vividion Therapeutics, Novartis, and Scorpion Therapeutics, holds equity options in Scorpion Therapeutics, receives grant support from Novartis, is a consultant to Aria Pharmaceuticals, and in the past 12 months received an honorarium from Astra-Zeneca, Roche, and New Equilibrium Biosciences. F.M. is a cofounder of and has equity in Harbinger Health, has equity in Zephyr AI, and serves as a consultant for Harbinger Health, Zephyr AI, and Red Cell Partners. F.M. declares that none of these relationships are directly or indirectly related to the content of this manuscript. The remaining authors declare no competing interests.
